Lenalidomide
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7060 publications
Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: June 17, 2026
Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: June 03, 2026
TARC levels in lenalidomide-induced rash during multiple myeloma treatment
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: June 03, 2026
Recent advances in management of systemic AL amyloidosis
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: June 03, 2026
A Single Center Real-World Study of the Efficacy of Daratumumab-Based Regimens in the Treatment of Relapsed/Refractory Multiple Myeloma Patients
Journal: Zhongguo shi yan xue ye xue za zhi
Published: June 02, 2026
Clinical Study and Economic Evaluation of High-Dose Etoposide Combined with Mecapegfilgrastim for Autologous Peripheral Blood Stem Cell Mobilization in Patients with Lymphoma
Journal: Zhongguo shi yan xue ye xue za zhi
Published: June 02, 2026
Response to comment on "Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: June 01, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Journal: The New England journal of medicine
Published: May 29, 2026
The Impact of Treatment Time Toxicity on Regimen Selection in Multiple Myeloma: A Single-Center Retrospective Study.
Journal: Internal medicine (Tokyo, Japan)
Published: May 24, 2026
Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
Journal: Leukemia & lymphoma
Published: May 22, 2026
Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 13, 2026
Last Updated: 06/30/2026